Member Info for LSBM

A charting view looking punchy on its way to 1300, expecting positive news. https://zakstraderscafe.com/bulletin-board-heroes-february-5-3/14231/

I know the business update lacked numbers, hence it's difficult to see the progress Trellus have made but they have advanced TrialSet™ integrations with pharma partners via CROs and direct deals. Although, full-scale rollout timelines remain tied to pilots, implementations, and renewals rather than firm dates. Just piecing together the progress we have:

ICON-Takeda (Mid-Stage Trial)

Deployment started post-October 2025 contract; program is now launching at sites with no specified full-scale date, though 12-month term suggests Q2 2026 ramp-up potential as performance milestones kick in.

PSI-Sanofi (Late-Stage Trials)

Implementation underway now; full launch targeted for mid-Q1 2026 (around March-April), marking quickest path to scale among CRO deals.

Pfizer (IBD Digital App)

Renewed Q2 2025 for patient support content; discussions ongoing for expansion ahead of 2026 renewal—no integration timeline given, but likely pilots first then broader rollout post-renewal.

Johnson & Johnson (Patient Support)

Signed January 2025; pilot achieved engagement/satisfaction metrics, with enrollment channels broadened mid-January 2026—indicates progressing to full scale in H1 2026 if metrics hold.

Expect PSI-Sanofi to hit full integration first (mid-Q1 2026), followed by ICON-Takeda and J&J (Q2 2026), with Pfizer lagging to late 2026; preferred vendor status with ICON/PSI could accelerate pharma access further. The pipeline is being built and revenue will follow. DYOR

Trellus Health’s latest RNS shows strong J&J IBD pilot progress: KPIs met, enrollment expanded. No formal renewal yet, but continuity signals more to come. Success positions Trellus for J&J trials via TrialSet—low resilience fix for attrition. Recent CRO deals (ICON, PSI) prove it. I see this as a commercial scale-up imminent, trial integration likely and revenue milestones ahead not just with J&J.

An underground traffic accident in which one worker sadly died; no one is currently being prosecuted, and the authorities are still investigating the circumstances. The company has notified the police and other relevant Brazilian authorities and is cooperating fully; until those enquiries are complete, no conclusions can be drawn about fault, negligence or criminality. This was an operational traffic accident underground, not an allegation of fraud, corruption or deliberate wrongdoing.

Management have publicly stated they had just completed a “superb year of health and safety performance,” and this fatality is a setback against what had been a strong run of safe operations. Public information confirms that fatalities are rare events for Serabi and that both recent deaths have been concentrated in a very short window, which is exactly why management are emphasising how unusual this is relative to their recent track record. You can reasonably say this is an unfortunate cluster against an otherwise good safety record, rather than evidence of a systematically unsafe operation.

They look like a short‑term operational interruption rather than a material hit to full‑year production guidance, unless regulators force broader shutdowns or systemic issues are found.

• At Coringa, the accident was at a production face, and Serabi has said production in the affected area is temporarily suspended, with other mining areas at the site continuing to operate.

• At Palito, the fatality was linked to an underground traffic accident, with production in the incident area paused for investigations but the company stating mining operations are otherwise unaffected.

In both cases, public statements indicate localised stoppages of specific zones, not a site‑wide shutdown.

How this feeds into annual ounces

• Serabi has indicated production in the affected areas is expected to resume within days once Brazilian authorities complete their inquiries.

• On that wording, the base case is a modest loss of output (days of production from a few faces) that is usually recoverable over a quarter, especially at a relatively small operation targeting c.50–57 koz in 2026

Agree, but recent Fed cuts respond to 'easing inflation' (CPI cooling to ~2.5% from peaks), aiming for a soft landing without recession—though Trump’s tariffs add upside risks, potentially validating your yield concern. Gilt curves may steepen short-term on policy bets, but long-end yields hinge on inflation durability.

Trump’s push for aggressive Fed rate cuts under Warsh risks hammering the dollar further amid easing inflation—lowering yields, spurring outflows, and eroding global confidence. Weaker USD = rocket fuel for gold prices, as investors flock to safe-haven bullion.

Comex up 1.6% on a 5-day view. THX is down 10% even after delivering PFS. Hopefully, rationality will kick in later.

Apologies, a genuine mistake. It's not Canaccord and they have not updated the target to 360p—formal broker consensus still lags, likely pre-dating gold’s surge to $3,500+/oz and Douta PFS. This figure stems from updating “The Oak Bloke” investor analysis (Substack), AI labelled as analyst, modeling FY25 net profits at ~138p/share from Segilola ramp-up (91koz+ at low AISC ~$900/oz), then applying a conservative 3.5x P/E multiple for high-momentum juniors (235% 1Y return): 138p x ~2.6 ≈ 360p midpoint, with 350-400p+ upside post-£1 barrier break. Douta PFS (Jan 2026) bolsters this: 1Moz over 12+ years, $908M NPV (73% IRR), $1,493/oz AISC yielding $561M cashflow at $3,500 gold—no dilution from $137M cash pile. This de-risks multi-asset growth (first gold 2028), justifying P/E re-rating beyond outdated broker notes.

I think analysts need to update their target price to help new investors in this share. On this site it still shows target 89 but I'm sure Canaccord Genuity have updated to 360.

Have listened to this interview again: https://www.cruxinvestor.com/posts/metals-exploration-runruno-cash-flows-finance-140k-oz-nicaragua-operation. There seems to be a lot of interest in JV with majors. Now, if they did pull that off, I wonder what that would do to the share price.

The Douta Gold Project, showed a robust global resource of approximately 1.75-1.78 million ounces of gold, with around 875,000 oz indicated and 909,000 oz inferred. Crucially, this PFS isn’t the endgame—ongoing exploration, including high-grade intercepts like 12m at 10.4 g/t Au and further drilling at northern licence areas, signals multiple phases of resource updates ahead. Investors should eye these phased uplifts, as they could push the resource well beyond 1.75 Moz, bolstering mine life and NPV in this high-margin West African asset.

Something is definitely coming, last 10-day avg vol 14k today, 40k already traded, and it's not even midday.

Definitely someone stocking up in blocks. 14m traded today vs 10-day Avg of 4.2m

Catalysts expected:

Completion and positive data readout from the one-year Johnson & Johnson pilot program for Trellus Elevate in IBD patients, launched in early 2025.

• Finalisation of late-stage contract negotiations with a leading global CRO for Trellus TrialSet in a mid-stage clinical trial (immunology/inflammation focus), plus progress on a second CRO collaboration.

• Potential new pharma collaborations or licensing deals, building on prior Pfizer renewal and two large pharma agreements; discussions ongoing across verticals.

This could rise to 1.8, which is where it was pre-funding issues, as the IP is worth more than the current valuation. Then, agree that it will need commercial deals to take this further.

It was mentioned on the weekend at Zak's Traders Cafe and again yesterday https://zakstraderscafe.com/bulletin-board-heroes-january-7-2/14030/, with a "punchy chart" earmarked to reach 30 and numerous possibilities still to be realised.

US Nicaragua sanctions aim to curb Ortega regime repression and human rights abuses by targeting state gold revenue—not private miners like MTL.

No current MTL impact

MTL’s La India project advances normally: 24% complete, plant en route, Q4 2026 production on track, funded from Philippines cash flows. No designations block construction, permits, or exports.

Future risk low, by design

Sanctions hit regime entities (e.g., Mines Directorate, ENIMINAS); compliant foreign juniors like MTL/Mako operate freely via non-sanctioned channels. US policy spares ethical operators to pressure dictators, not halt compliant mining.

Bottom line for MTL holders

Headline volatility possible, but no operational threat today or structurally ahead—sector tools target repression funding, leaving MTL’s value build intact. Diversify if nervous, but facts don’t justify panic selling.

The more people report it, the more priority they will give this. I've been told they have a technical workflow to resolve this. Meanwhile, got to go the old-fashioned phone route.

Timid, I can see why you would suggest Segilola, maybe first, as this in turn will fund Douta; however, Segilola’s resource update is expected in Q1 2026, after the Douta PFS. 
Segilola drilling updates have been ongoing through Q4 2025, but the company explicitly states an updated resource “as of end of 2025” with release planned for Q1 2026, following assay integration and consultant review. Looking at the presentations, management prioritises Douta as the “second mine” milestone. Segilola extension remains exploratory (testing high-grade shoots at depth), needing more dry-season drilling into 2026 before a formal resource can be declared, and economic scoping follows. In any case, if we factor in Segilola, we are looking at more than 4 times today's SP, although the devil is in the detail.